☰

Corteria Pharmaceuticals

One evidence chain from bench to bedside

Industry
Biotechnology
Headquarters
Paris, France
Public information as of
March 2026

A4BEE prepared this analysis from publicly available sources. It reflects our own reading of Corteria Pharmaceuticals's published strategy and is not endorsed by, or produced in cooperation with, Corteria Pharmaceuticals. Company website

Strategic priorities

Corteria Pharmaceuticals is a Paris-based clinical-stage biotechnology company founded in May 2021 by former Sanofi cardiovascular researchers Philip Janiak and Marie-Laure Ozoux. The company is developing first-in-class drugs for underserved heart failure subpopulations, anchored by its CRF2 (corticotropin-releasing factor type 2) receptor agonist platform. As of late 2023 the company had raised $83.3 million across a $13.6 million seed round in December 2021 and a $69.7 million oversubscribed Series A in September 2023 led by OrbiMed and Jeito Capital.

The lead programme, COR-1167, is in the Phase 2b CRAFT-WHF trial (NCT06815471) for worsening heart failure, recruiting across the United States, the Czech Republic, and Spain. A second CRF2 agonist, COR-1389, is positioned for right heart failure, sarcopenia and obesity-related indications, and a preclinical AVP (arginine vasopressin) neutralising monoclonal antibody targets acute heart failure with hyponatremia. Manufacturing for all three programmes relies on contract development and manufacturing organisations (CDMOs) for solid-phase peptide synthesis, purification and sterile fill-finish.

The operational priority sits at the intersection of clinical, manufacturing and regulatory data. The Phase 2b protocol produces heterogeneous streams (haemodynamics, biomarker panels, echocardiography, patient-reported outcomes) across geographically dispersed sites; COR-1167 and COR-1389 each require distinct dosing schedules and stability programmes; and the first-in-class CRF2 mechanism has no prior regulatory precedent to reference, meaning FDA (Food and Drug Administration) and EMA (European Medicines Agency) submissions need unusually complete documentation. Pulling these three streams into one regulatory-ready evidence chain is what the company is now building.

Membership in the Future4Care digital health ecosystem gives Corteria access to wearable-device technologies for continuous congestion and fluid-status monitoring, and the company has indicated that integrating these data into trial workflows is part of its longer-term clinical evidence plan. The current IT estate is closer to a lean biotech baseline than to a multi-site clinical operations stack, so the work in front of the company is to put the data plumbing in place before the next phase of trials compounds its complexity.

Challenges we see

  • Operations Manufacturing

    Scaling peptide manufacturing across two molecules

    Corteria is advancing two CRF2 agonists with different dosing regimens (COR-1167 once-daily subcutaneous, COR-1389 once-monthly subcutaneous), each requiring specialised solid-phase peptide synthesis, purification, sterile fill-finish and stability validation through external CDMO partners.

    Two peptide programmes run through the same CDMO pipeline with different release schedules, so process knowledge and quality evidence built for one programme need to be carried over to the other without re-establishing the same controls each time.

  • Digital Integration

    Harmonising data from a global Phase 2b trial

    The CRAFT-WHF Phase 2b trial recruits across sites in the United States (Indiana, Oklahoma, North Carolina), the Czech Republic, and Spain (Madrid, Murcia, Valencia), and captures haemodynamic monitoring, biomarker panels, echocardiography and quality-of-life assessments that must converge into a single regulatory submission package.

    Where data from each site moves through its own collection path, the differences between sites become differences between dossiers; an agreed data model and ingestion path up front keeps the cross-site comparison inside the protocol rather than inside the reconciliation step.

  • Digital Operations

    Selecting trial candidates from multi-modal phenotyping

    The Phase 0 observational study combined biomarkers, echocardiography and clinical assessments to identify residual congestion signatures, and that phenotyping approach is intended to feed directly into the Phase 2b enrolment criteria.

    When the same patient profile drives a screening decision and a downstream endpoint read-out, the data behind that profile has to be findable in the trial record by both the enrolment team and the clinical operations team, which moves deep phenotyping from a one-off study into a recurring evidence input.

  • Compliance Regulatory

    Documenting first-in-class mechanisms for FDA and EMA

    CRF2 agonism has no prior approved precedent, so biomarker qualification, safety monitoring and pharmacovigilance infrastructure must be built from the ground up for both FDA and EMA review pathways, on top of standard Good Manufacturing Practice (GMP) and Good Clinical Practice (GCP) evidence.

    Where the regulatory frame for a new mechanism is built case by case, the speed at which a complete, internally consistent document set is assembled starts to set the calendar for the next regulatory interaction, so the document pipeline itself becomes a clinical milestone.

  • Digital Integration

    Bringing wearable data into the trial evidence chain

    Through membership in the Future4Care digital health ecosystem, Corteria has access to wearable devices and remote monitoring intended to capture continuous congestion and fluid-status data alongside the in-clinic assessments of the CRAFT-WHF trial.

    Wearables generate data at a different cadence and a different provenance from in-clinic measurements, so combining the two streams inside one evidence chain is an integration design question rather than a tooling question.

Opportunities, by urgency and business impact

Each bubble is one opportunity, numbered to match the list below. Further right means it bites sooner; higher means a bigger effect on the business. A bigger bubble means a bigger implementation effort.

Source: A4BEE analysis of public sources

  1. Unifying multi-site trial data into one regulatory-ready model

    CRAFT-WHF captures haemodynamic, biomarker, imaging and patient-reported outcomes across sites in three countries, with no shared platform for real-time aggregation or for compiling a CDISC/SDTM-compliant (Clinical Data Interchange Standards Consortium / Study Data Tabulation Model) submission package.

    An ontology-driven platform that loads each site's output against one shared model lets the trial team monitor endpoints in real time and assembles the submission data package as the trial runs, rather than after it.

    • Corteria, CRAFT-WHF trial registration (NCT06815471), ClinicalTrials.gov
    • Corteria, Scientific narrative and pipeline overview, company website

  2. Automating phenotyping to predict CRF2 responders

    Phase 0 deep phenotyping identified residual congestion signatures across biomarkers, echocardiography and clinical scores, but turning those signatures into a repeatable patient-selection step for Phase 2b enrolment is currently manual.

    AI-driven analytics that score each candidate against the phenotyping model shorten the time from screening visit to enrolment decision and keep the responder profile consistent as the trial grows.

    • Corteria, Phase 0 observational study design, company communications
    • Philip Janiak commentary on cardiovascular trial heterogeneity, public interview

  3. Gaining real-time visibility into CDMO peptide production

    COR-1167 and COR-1389 are made at external CDMO sites under GMP, but Corteria has no live view of production parameters, batch quality or deviations during the runs that supply its clinical trials.

    A secure gateway into the CDMO's production systems, with statistical process control on critical quality attributes, gives Corteria the same view of a batch that the CDMO operator has, and produces a digital batch record that survives the regulatory review.

    • Corteria CMC (Chemistry, Manufacturing and Controls) operating model, company overview
    • Industry guidance on GMP peptide manufacturing and CDMO oversight

  4. Wearable monitoring as a clinical endpoint input

    The Future4Care ecosystem gives Corteria access to wearable devices for continuous fluid-status and congestion monitoring, but the data path from these devices into the trial record has not been built.

    An IoT (Internet of Things) ingestion layer that brings wearable data into the same model as in-clinic assessments opens the door to continuous endpoint analysis and to earlier intervention signals for trial investigators.

    • Future4Care digital health ecosystem, programme description
    • Corteria commentary on remote monitoring in heart failure trials

  5. Assembling regulatory and clinical documents from system records

    FDA and EMA submissions for a first-in-class mechanism require unusually complete biomarker qualification, safety monitoring and pharmacovigilance documentation, and much of that content is currently re-typed from source systems when a document is due.

    Narrow AI agents draft first versions of these documents from the underlying system records, check each draft against its template before review, and trace every figure back to the source it came from, so a named reviewer approves the output rather than builds it.

    • Industry commentary on FDA and EMA submissions for first-in-class mechanisms
    • Corteria pipeline and regulatory strategy, company materials

What we'd propose

  • Enterprise AI

    Ontology-driven platform for the CRAFT-WHF Phase 2b trial

    A shared data platform that defines the entities of the CRAFT-WHF trial (haemodynamic measurement, biomarker result, echocardiography finding, patient-reported outcome, site, subject, visit) once, then loads each site's output against that single model so the trial team sees one consistent view of the data and assembles the CDISC/SDTM submission package from it.

    • Shared clinical trial ontology

      One agreed set of terms

      Define haemodynamic, biomarker, imaging and patient-reported outcome entities with explicit relationships and units, so data from the United States, the Czech Republic and Spain sites loads against one model rather than three dialects of the same concept.

    • Site ingestion and validation

      Loading every site cleanly

      Build the data pipelines for each trial site's source systems (electronic data capture, central laboratory, imaging core lab) with schema validation at the boundary so a bad record fails loudly instead of silently.

    • Submission-ready analytics

      CDISC/SDTM output as a by-product

      Expose the model through dashboards for interim safety and endpoint review, and through a transformation layer that produces CDISC/SDTM datasets for FDA and EMA submissions without a separate end-of-trial data freeze.

    • The trial team monitors endpoints in real time instead of waiting for a quarterly reconciliation.
    • The CDISC/SDTM submission package is produced as the trial runs, not after it ends.
    • Site-to-site data differences are caught at ingestion rather than at regulatory review.

    We've done this before

    See how we do Enterprise AI
  • Digital Lab

    AI-assisted patient stratification for responder prediction

    A machine learning pipeline that scores each screening candidate against the residual congestion signature model from the Phase 0 study, so site investigators see a predicted response likelihood alongside the conventional enrolment criteria.

    • Phenotyping model from Phase 0 data

      A reusable responder signature

      Train the responder model on the Phase 0 deep-phenotyping cohort, with biomarker, echocardiography and clinical score inputs, so the same model that identified the signature can score new candidates against it.

    • Predictive enrolment scoring

      A ranking at the screening visit

      Surface the predicted response score to site investigators at the screening visit, so high-probability responders can be prioritised and the rationale for each scoring decision is preserved alongside the candidate's record.

    • Cohort and site analytics

      Adaptive trial design inputs

      Build the analytics that show how the enrolled cohort compares to the Phase 0 reference population, so interim analyses can flag when the trial is drifting away from the responder profile it was designed for.

    • Enrolment decisions use the same responder profile that defined the trial.
    • Statistical power is protected because selection bias is reduced and documented.
    • Interim analyses can adjust the design before the trial is too far committed to it.

    We've done this before

    See how we do Digital Lab
  • Digital CDMO

    Real-time visibility into CDMO peptide manufacturing

    A secure gateway into the CDMO's peptide production systems for COR-1167 and COR-1389, with statistical process control on critical quality attributes and a digital batch record that satisfies 21 CFR Part 11 (the US Food and Drug Administration's rule on electronic records and electronic signatures) and EU Annex 11.

    • CDMO process data gateway

      Secure connection to the production line

      Deploy an IoT-based data gateway at the CDMO partner site that captures process parameters from solid-phase peptide synthesis, purification and fill-finish without disturbing the validated GMP workflow already in place.

    • Critical quality attribute monitoring

      Deviations flagged during the run

      Build statistical process control models on the critical quality attributes of each peptide programme, so a deviation is flagged against the batch that is running rather than the batch that has already shipped.

    • Digital batch record with 21 CFR Part 11 audit trail

      GMP documentation that holds up

      Assemble each batch record digitally with electronic signatures and a complete audit trail, satisfying FDA 21 CFR Part 11 and EU Annex 11 so the documentation stands on its own during an inspection.

    • Batch deviations surface during the run rather than after release.
    • One set of process data serves manufacturing, quality and regulatory instead of three separate extracts.
    • CDMO oversight does not require a Corteria engineer on site for every batch.

    We've done this before

    See how we do Digital CDMO
  • Agents

    AI agents for regulatory and clinical document work

    Narrow, reviewable agents that take the repetitive part of regulatory and clinical document work: drafting deviation and change-control summaries from source records, checking each document against its FDA or EMA template before review, and finding every controlled document a standards change affects. A named reviewer approves every output.

    • Drafting from system records

      First drafts from the source data

      Generate the first draft of a regulatory summary, a clinical study report section or a pharmacovigilance narrative directly from the underlying system records, so the author edits and judges rather than assembles.

    • Template and completeness checking

      Gaps found before review

      Check a submitted document against the relevant FDA or EMA template and the company's own checklist, returning missing or inconsistent sections before the document enters the human review queue.

    • Change impact search across the document set

      Which documents a change touches

      When a guideline, method or specification changes, retrieve every controlled document that references it and rank them by how directly they are affected, so the update scope is known on day one.

    • Regulatory review queues move faster because documents arrive complete.
    • Every figure in a submission is traceable to the source record it came from.
    • The scope of a guideline change is established by search rather than by recollection.

    We've done this before

    See how we do Agents

Digital maturity: today and target

Scored out of 100 across six dimensions. The target is what Corteria Pharmaceuticals's own published ambition implies — not a perfect score.

Source: A4BEE analysis of public sources
Trial data integration 25 → 78
CRAFT-WHF generates haemodynamic, biomarker, imaging and patient-reported outcomes across sites in three countries, but the estate is closer to a lean biotech baseline than to a multi-site clinical operations stack; assembling a CDISC/SDTM submission package as a by-product of the trial model is the target.
Manufacturing process data 20 → 70
Both peptide programmes run through external CDMO partners under GMP, with batch records and deviation tracking predominantly paper-based at Corteria's side; bringing process data in as a continuous feed is the path to that target.
Remote patient monitoring 15 → 65
Future4Care membership gives Corteria access to wearable devices, but no operational pipeline exists yet for integrating wearable data into the trial record; the target assumes that pipeline is in place alongside the trial data model.
Cybersecurity and compliance 30 → 82
Patient data, CDMO connections and wearable endpoints span jurisdictions (United States, European Union), raising the bar for GDPR (General Data Protection Regulation), 21 CFR Part 11 and EMA digital evidence requirements; continuous audit evidence is the destination.
AI for stratification 20 → 72
The Phase 0 deep-phenotyping study built the conceptual foundation for responder prediction, but operational models for biomarker pattern recognition and predictive enrolment scoring are not yet deployed; the target sits at routine use during Phase 2b.
Cloud and IT foundation 25 → 72
The current IT estate supports a Series A biotech at one site; a purpose-built cloud platform for trial data, CDMO integration and regulatory submission workflows is the destination, and is sized to a lean clinical-stage operation rather than a global enterprise.

Check this yourself

Our Service Portal has free self-assessments and market comparisons. These are the ones that line up with what we've read above — no sales call required.

Think we've read this right?

Talk to us

Related reading

This is an independent analysis prepared by A4BEE from publicly available information as of March 2026. It reflects A4BEE's own interpretation and opinion, is not affiliated with, endorsed by, or verified with Corteria Pharmaceuticals, and may be incomplete or inaccurate. All company names and trademarks are the property of their respective owners. To request a correction or removal, contact [email protected].